Your session is about to expire
← Back to Search
Other
Open-label treatment arm for Atopic Dermatitis
Phase 1
Waitlist Available
Research Sponsored by Dermavant Sciences GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and female pediatric patients aged 2 to 11 with confirmed diagnosis of atopic dermatitis by Hanifin and Rajka criteria.
Patients with atopic dermatitis covering > 25% of the body surface area and with an Investigator Global Assessment of disease severity of 2 or greater at baseline.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
Study Summary
This is a multicenter, open-label Phase 1b study in pediatric patients age 2-11 years old with extensive atopic dermatitis.
Eligible Conditions
- Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency and severity of adverse events (local and systemic)
Laboratory values
Plasma concentrations of M11 metabolite
+2 moreSecondary outcome measures
Efficacy - 2-point improvement in IGA
Efficacy - Body Surface Area (BSA)
Efficacy - EASI-50
+6 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Open-label treatment armExperimental Treatment1 Intervention
Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
Find a Location
Who is running the clinical trial?
Dermavant Sciences GmbHLead Sponsor
12 Previous Clinical Trials
3,102 Total Patients Enrolled
James Lee, MD, PhDStudy ChairDermavant Sciences, Inc.
2 Previous Clinical Trials
267 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger